N@N

Edward Nash Maintained (TVTX) at Strong Buy with Decreased Target to $42 on, Feb 28th, 2023

Edward Nash of Canaccord Genuity, Maintained "Travere Therapeutics, Inc." (TVTX) at Strong Buy with Decreased Target from $44 to $42 on, Feb 28th, 2023.

Edward has made no other calls on TVTX in the last 4 months.

There are 5 other peers that have a rating on TVTX. Out of the 5 peers that are also analyzing TVTX, 1 agrees with Edward's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Alex Thompson of "Stifel" Initiated at Hold and Held Target at $22 on, Wednesday, December 14th, 2022

These are the ratings of the 4 analyists that currently disagree with Edward

---

• Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Friday, February 24th, 2023
• Laura Chico of "Wedbush" Upgraded from Hold to Buy and Held Target at $30 on, Tuesday, February 21st, 2023
• Carter Gould of "Barclays" Maintained at Buy with Decreased Target to $31 on, Tuesday, February 21st, 2023
• Do Kim of "Piper Sandler" Maintained at Buy with Increased Target to $46 on, Tuesday, February 21st, 2023

Contributing Sources

---